Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT.
McLornan DP, Gras L, Martin I, Sirait T, Schroeder T, Blau IW, Kuball J, Byrne J, Collin M, Stadler M, Desmier D, Salmenniemi U, Jindra P, Mikhailova N, Lenhoff S, Rifón J, Robin M, Rovira M, Veelken H, Sadowska-Klasa A, Zecca M, Hayden PJ, Czerw T, Hernández-Boluda JC, Yakoub-Agha I. McLornan DP, et al. Br J Haematol. 2022 Jul;198(1):209-213. doi: 10.1111/bjh.18219. Epub 2022 Apr 28. Br J Haematol. 2022. PMID: 35482558 No abstract available.
Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation.
Cervantes F, Hernández-Boluda JC, Odriozola J, Camós M, Villalón L, Martínez-Climent JA, del Campo R, García-Conde J, Montserrat E. Cervantes F, et al. Br J Haematol. 2003 Feb;120(3):500-4. doi: 10.1046/j.1365-2141.2003.04077.x. Br J Haematol. 2003. PMID: 12580969 Free article. Clinical Trial.
Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, Beelen D, Socié G, Bornhäuser M, Angelucci E, Niederwieser D, Gerbitz A, Finke J, Vitek A, Itälä-Remes M, Radujkovic A, Kanz L, Potter V, Chevallier P, Stelljes M, Petersen E, Robinson S, Poiré X, Klyuchnikov E, Hernández-Boluda JC, Czerw T, Hayden P, Kröger N, Yakoub-Agha I. McLornan D, et al. Biol Blood Marrow Transplant. 2019 Nov;25(11):2167-2171. doi: 10.1016/j.bbmt.2019.06.034. Epub 2019 Jul 5. Biol Blood Marrow Transplant. 2019. PMID: 31284069 Free article.
Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation.
Hernández-Boluda JC, Pereira A, Kröger N, Beelen D, Robin M, Bornhäuser M, Angelucci E, Vitek A, Blau IW, Niittyvuopio R, Finke J, Cornelissen JJ, Passweg J, Dreger P, Petersen E, Kanz L, Sanz J, Zuckerman T, Zinger N, Iacobelli S, Hayden P, Czerw T, McLornan D, Yakoub-Agha I. Hernández-Boluda JC, et al. Leukemia. 2021 Jan;35(1):215-224. doi: 10.1038/s41375-020-0815-z. Epub 2020 Apr 14. Leukemia. 2021. PMID: 32286544
Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.
Montoro J, Roldán E, Piñana JL, Barba P, Chorão P, Quintero A, Hernani R, Ortí G, Lorenzo JI, Balaguer-Roselló A, Salamero O, Fox L, Solves P, Gómez I, Guerreiro M, Hernández Boluda JC, Sanz G, Solano C, Sanz MÁ, Valcárcel D, Sanz J. Montoro J, et al. Eur J Haematol. 2021 Jan;106(1):114-125. doi: 10.1111/ejh.13529. Epub 2020 Oct 18. Eur J Haematol. 2021. PMID: 33025625
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT).
Polverelli N, Mauff K, Kröger N, Robin M, Beelen D, Beauvais D, Chevallier P, Mohty M, Passweg J, Rubio MT, Maertens J, Finke J, Bornhäuser M, Vrhovac R, Helbig G, Mear JB, Castagna L, Reményi P, Angelucci E, Karakasis D, Rifòn J, Sirait T, Russo D, de Wreede L, Czerw T, Hernández-Boluda JC, Hayden P, McLornan D, Yakoub-Agha I. Polverelli N, et al. Am J Hematol. 2021 Jan;96(1):69-79. doi: 10.1002/ajh.26020. Epub 2020 Oct 27. Am J Hematol. 2021. PMID: 33064301 Free article. Clinical Trial.
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT.
Battipaglia G, Mauff K, Wendel L, Angelucci E, Mohty M, Arcese W, Santarone S, Rubio MT, Kroger N, Fox ML, Blaise D, Iori AP, Fanin R, Chalandon Y, Pioltelli P, Marotta G, Chiusolo P, Sever M, Solano C, Contentin N, de Wreede LC, Czerw T, Hernandez-Boluda JC, Hayden P, McLornan D, Yakoub-Agha I. Battipaglia G, et al. Bone Marrow Transplant. 2021 Jul;56(7):1593-1602. doi: 10.1038/s41409-021-01222-z. Epub 2021 Feb 1. Bone Marrow Transplant. 2021. PMID: 33526919
Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT.
Nabergoj M, Mauff K, Robin M, Kröger N, Angelucci E, Poiré X, Passweg J, Radujkovic A, Platzbecker U, Robinson S, Rambaldi A, Petersen SL, Stölzel F, Stelljes M, Ciceri F, Mayer J, Ladetto M, de Wreede LC, Koster L, Hayden PJ, Czerw T, Hernández-Boluda JC, McLornan D, Chalandon Y, Yakoub-Agha I. Nabergoj M, et al. Bone Marrow Transplant. 2021 Aug;56(8):1944-1952. doi: 10.1038/s41409-021-01271-4. Epub 2021 Apr 6. Bone Marrow Transplant. 2021. PMID: 33824436
236 results